Blood thinners are an important medicine for many people with heart disease. These drugs help prevent dangerous blood clots from forming inside blood vessels. When clots block blood flow, they can cause heart attacks or strokes, which are among the leading causes of death worldwide.
For this reason, blood thinners are commonly prescribed after certain heart procedures, especially a treatment called percutaneous coronary intervention, often shortened to PCI. This procedure is widely used to treat blocked arteries that supply blood to the heart. During PCI, doctors insert a small tube called a stent into a narrowed or blocked artery.
The stent acts like a tiny scaffold that keeps the artery open, allowing blood to flow more freely to the heart muscle. While the procedure is highly effective, the presence of a stent can sometimes lead to blood clots forming around it. If a clot develops inside the stent, it can block the artery again and cause a serious heart attack.
To reduce this risk, doctors usually prescribe blood thinners after the procedure. Many patients take a combination of two blood-thinning medications, often called dual antiplatelet therapy. This treatment significantly lowers the chance of clots forming inside the stent.
However, using more than one blood thinner for a long time can also increase the risk of bleeding, which can sometimes be serious. For doctors, one of the biggest challenges is deciding how long patients should continue taking multiple blood thinners after PCI.
Some patients may benefit from longer treatment, while others may face higher risks from bleeding complications. To help answer this question, researchers recently examined guidelines developed by the European Society of Cardiology, also known as the ESC.
These guidelines are widely used by doctors around the world to help guide treatment decisions for heart disease. The ESC guidelines suggest that certain patients may benefit from staying on blood thinners for a longer period of time after PCI. These are usually patients who have a higher chance of developing future heart problems.
For example, people who previously had a heart attack, those living with diabetes, patients with chronic kidney disease, and individuals with severe coronary artery disease may face greater risks of complications after their procedure.
For these patients, longer use of blood thinners may offer extra protection against heart attacks or other serious events. To better understand how these guidelines work in real-world situations, researchers conducted a large study involving nearly twelve thousand patients who had undergone PCI procedures.
The study examined medical records from 11,787 patients treated between 2012 and 2019 at a major medical center. The scientists divided the patients into three groups based on their level of risk according to the ESC guidelines. These groups were classified as low risk, moderate risk, and high risk for developing future heart problems.
The researchers then followed the patients for one year after their procedure to see how they fared. They focused on a group of serious outcomes known as major adverse cardiovascular events, often called MACE. This category includes major health problems such as heart attacks and death from any cause.
In addition to these events, the scientists also looked at cases of major bleeding, which is an important side effect associated with long-term blood thinner use. The results of the study showed clear differences between the risk groups.
Patients in the moderate-risk and high-risk groups experienced more major cardiovascular events compared with those in the low-risk group. In particular, these patients had higher rates of heart attacks and deaths during the follow-up period. However, the study also found that patients in the high-risk group were more likely to experience major bleeding.
This highlights the difficult balance doctors must consider when deciding how long blood thinners should be used. While longer treatment can help prevent heart attacks, it can also increase bleeding risk. The study’s lead author, Dr. George Dangas, explained that these findings highlight the importance of personalized treatment in cardiology.
Rather than using the same approach for every patient, doctors should carefully evaluate each person’s individual health conditions and risk factors. By considering factors such as previous heart attacks, diabetes, kidney disease, and the severity of coronary artery disease, doctors can better determine who may benefit from extended blood thinner therapy.
Dr. Dangas, who also serves as President-Elect of the Society for Cardiovascular Angiography and Interventions, believes that studies like this help move heart care toward a more personalized approach.
Using tools such as the ESC guidelines may help doctors identify which patients are most likely to benefit from longer treatment and which patients should avoid the added risk of bleeding. The research was presented at the 2023 Scientific Sessions of the Society for Cardiovascular Angiography and Interventions.
It adds valuable evidence supporting the use of ESC guidelines to guide treatment decisions after PCI procedures. By helping doctors tailor treatment plans to each patient’s risk profile, this approach may improve outcomes and reduce complications in people living with heart disease.
As medical research continues to advance, personalized strategies like this are becoming an important part of modern heart care. Doctors hope that better risk assessment tools will allow them to provide safer and more effective treatments for patients recovering from coronary artery procedures.
If you care about heart disease, please read studies that herbal supplements could harm your heart rhythm, and how eating eggs can help reduce heart disease risk.
For more health information, please see recent studies that apple juice could benefit your heart health, and results showing yogurt may help lower the death risks in heart disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
